RA Capital Healthcare Fund LP 4
4 · Vor Biopharma Inc. · Filed Apr 15, 2026
Research Summary
AI-generated summary of this filing
Vor Biopharma (VOR) 10% Holder RA Capital Sells $11.9M Shares
What Happened
RA Capital Management, L.P. (a reported 10% holder and investment manager for RA Capital Healthcare Fund) sold a total of 737,989 shares of Vor Biopharma (VOR) in open‑market or private sales across April 13–15, 2026. The three disposals were: 530,610 shares at a weighted average of $16.15 (≈ $8,569,352) on 2026‑04‑13; 153,735 shares at a weighted average of $15.97 (≈ $2,455,148) on 2026‑04‑14; and 53,644 shares at a weighted average of $16.01 (≈ $858,840) on 2026‑04‑15. Total proceeds across the three dates were approximately $11.88 million. These were sales (not purchases), which are commonly routine portfolio transactions for institutional holders.
Key Details
- Transaction dates and reported weighted averages:
- 2026‑04‑13: 530,610 shares @ $16.15 (weighted avg; reported range $15.94–$16.32) — F1
- 2026‑04‑14: 153,735 shares @ $15.97 (weighted avg; reported range $15.75–$16.17) — F4
- 2026‑04‑15: 53,644 shares @ $16.01 (weighted avg; reported range $16.005–$16.10) — F5
- Aggregate sold: 737,989 shares for roughly $11.88M in proceeds.
- Holdings after the transactions: not specified in the provided filing details.
- Footnotes / ownership structure:
- Shares were held directly by RA Capital Healthcare Fund, L.P. (the Fund) — F3.
- RA Capital Management, L.P. is the Fund’s investment manager; the Adviser, its GP, and named individuals disclaim beneficial ownership except for any pecuniary interest — F2.
- Filing notes weighted‑average pricing and provides price ranges for the multiple transaction executions (F1, F4, F5); the filer offers to provide per‑trade price breakdowns on request.
- Board connection: Dr. Andrew Levin, a partner/managing director of the Adviser, serves on Vor’s board (reported in Remarks).
- Timeliness: Filing date Apr 15, 2026 for transactions through Apr 15 appears timely under standard Form 4 reporting windows.
Context
- This Form 4 reports institutional disposals by a 10% holder (an investment fund/manager relationship), not an executive exercising options or receiving awards. Institutional sales often reflect portfolio rebalancing and do not by themselves indicate management sentiment about the company’s prospects.
- No purchases, option exercises, gifts, or tax‑withholding events were reported in this filing.
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-04-13$16.15/sh−530,610$8,569,352→ 3,404,998 total(indirect: See footnotes) - Sale
Common Stock
[F4][F2][F3]2026-04-14$15.97/sh−153,735$2,455,148→ 3,251,263 total(indirect: See footnotes) - Sale
Common Stock
[F5][F2][F3]2026-04-15$16.01/sh−53,644$858,840→ 3,197,619 total(indirect: See footnotes)
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.94 to $16.32 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.75 to $16.17 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.005 to $16.10 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.